Fig. 1 · Structure

Documents & Downloads

Tipifarnib (Zarnestra)

Cat. No. A10935 CAS 192185-72-1

FTase inhibitor

Tipifarnib (Zarnestra) is a farnesyltransferase inhibitor that inhibits the Ras kinase in a post translational modification step before the kinase pathway becomes hyperactive.

In Stock

Publications for Tipifarnib

1 publication citing this product

  1. Xiaoming Liu, .et al. , J Immunother Cancer, 2022, Apr;10(4):e004399 PMID: 35483745

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Consistent with farnesyltransferase inhibition, tipifarnib (200 nM, 48 h) altered HRAS processing in both HRAS-mutant and wild-type HNSCC cells. HRAS-GFP imaging in 293 cells showed redistribution toward the cytosol. These cellular endpoints do not provide an enzyme IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
FTase 0.6 nM

Cellular Effect

Cell Line Activity Value Description Reference
Capan-2 IC50 16 nM Antiproliferative activity against human Capan-2 cells harboring KRAS 12 mutation assessed as inhibition of cell growth incubated for 4 to 7 days [PMID: 33228976]
HT1197 IC50 1.7 nM Antiproliferative activity against human HT1197 cells harboring HRAS 61 mutation assessed as inhibition of cell growth incubated for 4 to 7 days [PMID: 33228976]
MCF7 IC50 3.08 μM Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay 10.1039/C3MD00058C
NCI-H441 IC50 36 nM Antiproliferative activity against human NCI-H441 cells harboring KRAS 12 mutation assessed as inhibition of cell growth incubated for 4 to 7 days [PMID: 33228976]
NIH3T3 EC50 4 nM Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in rat 3T3 cells after 7 days by alamar blue assay [PMID: 20429511]
Sf9 IC50 0.7 nM Inhibition of rat recombinant PFT expressed in insect Sf9 cells by scintillation proximity assay [PMID: 20429511]
Sf9 IC50 0.7 nM Inhibition of rat recombinant protein farnesyltransferase expressed in Sf9 cells by [3H]-scintillation proximity assay [PMID: 19239254]
SU.86.86 IC50 9.5 nM Antiproliferative activity against human SU-86-86 cells harboring KRAS 12 mutation assessed as inhibition of cell growth incubated for 4 to 7 days [PMID: 33228976]

Tipifarnib (Zarnestra) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Tipifarnib (Zarnestra) from 2 published references. In vitro models include 9464D-GD2 mouse neuroblastoma cells.

Tipifarnib (Zarnestra) In Vitro Studies

In 9464D-GD2 neuroblastoma cells, 0.1 µM tipifarnib for 48 h reduced the concentration of sEV particles recovered from conditioned medium versus DMSO (n=4; p<0.001). The preparation was normalized to cell count; this endpoint does not establish selective inhibition of vesicle secretion or clinical benefit. [2]

Cellular HRAS processing and localization

Cell-based study · UMSCC17B and ORL214 (HRAS mutant), CAL27 (HRAS wild type); HRAS-GFP-expressing 293 cells for localization. [1]

At 200 nM for 48 h, tipifarnib altered HRAS immunoblot mobility in both mutant and wild-type HNSCC cells. In a separate localization readout within the same target-engagement analysis, HRAS-GFP became more cytosolic. These are cellular processing/localization endpoints, not a purified-enzyme potency measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HRAS electrophoretic mobility in mutant and wild-type HNSCC cellsQualitative immunoblot shift HRAS mobility shift consistent with inhibited prenylation in UMSCC17B, ORL214 and CAL27.[1]
HRAS-GFP localization in transfected 293 cellsQualitative localization More cytosolic HRAS-GFP after tipifarnib versus control; no numerical effect size extracted.[1]

Literature-Reported Treatment Conditions

Treatment concentration
200 nM
Exposure duration
48 h
Method
Cell treatment followed by HRAS immunoblot and confocal localization analysis
Vehicle
DMSO (0.2%) specified for Fig 2B; Fig 2D labels CTRL without an explicit vehicle concentration.
Reported limits
Replication counts and quantified localization effect size are not supplied in Fig 2 caption; supplemental preparation details not retrieved.
Methods and source locations

Compound reported in the paper: Tipifarnib; Compound label in the paper: Tipifarnib

Literature results for the named compound; tested material was supplied by Kura Oncology.

Results S13; Fig 2B-D and caption; Methods: HRAS plasma membrane translocation assays and Tipifarnib

HRAS electrophoretic mobility in mutant and wild-type HNSCC cells: 18% gel; GAPDH loading control; treated versus DMSO control. — Fig 2B and caption; Results S13

HRAS-GFP localization in transfected 293 cells: Confocal imaging; HRAS-GFP expression verified by immunoblot in panel C. — Fig 2C-D and caption; Results S13; Methods translocation assays

Recovery of extracellular vesicles from tipifarnib-treated neuroblastoma cells

Cell-based study · 9464D-GD2 mouse neuroblastoma cells. [2]

Treatment with 0.1 µM tipifarnib for 48 h reduced sEV particle concentration recovered from conditioned medium versus DMSO. Preparations were normalized to cell number. The viability-control identity differs between the supplemental methods (9464D-GD2) and Fig S7B caption (9464D), so no model-specific absence-of-cytotoxicity claim is adopted.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
sEV particle concentration recovered from conditioned mediumNTA particle concentration comparison Lower than DMSO control; mean±SD, n=4; ***p<0.001 (Student’s t-test). Exact means not extracted.[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 µM
Exposure duration
48 h
Method
Conditioned-medium sEV isolation and nanoparticle tracking analysis; preparation normalized to cell count.
Vehicle
DMSO; final percentage not stated in selected experiment.
Reported limits
No exact particle means or effect size digitized. Model identity of the supplemental viability control is inconsistent across the source.
Methods and source locations

Compound reported in the paper: Tipifarnib; Compound label in the paper: Tipifarnib

Literature results for named tipifarnib; supplier attribution is not experiment-specific.

Fig 4A-C and caption; Results s3-4; Supplement p3 NTA methods and p21 Fig S7B caption; main drug and sEV methods

sEV particle concentration recovered from conditioned medium: NanoSight NS300; cell-number-normalized sEV preparation described in supplemental NTA methods. — Fig 4B-C and caption; Supplement p3, Nanoparticle tracking analysis

Tipifarnib (Zarnestra) In Vivo Studies

Oral tipifarnib (60 mg/kg twice daily) suppressed tumor growth in four HRAS-mutant HNSCC PDX models relative to vehicle (n=3 per group). Six wild-type PDXs showed positive tumor-volume changes during treatment. Responses are specific to this model panel and do not establish durable tumor control. [1]

In immunocompetent mice bearing 9464D-GD2 tumors, tipifarnib plus dinutuximab reduced tumor growth and weight more than either agent alone. sEV add-back reversed tipifarnib’s single-agent effect, but the tumor-weight increase after add-back to the combination was not statistically significant (p=0.086). Other farnesylation-dependent mechanisms may contribute. [2]

HRAS-stratified HNSCC patient-derived xenograft response

Animal study · HNSCC PDX panel in athymic nude mice: four HRAS-mutant models and six HRAS-wild-type models. [1]

Four mutant PDXs showed tumor growth suppression relative to vehicle. Six wild-type PDXs showed positive tumor-volume change during treatment in the waterfall plot. The acquired main figure supports this contrast; the wild-type vehicle curves in supplemental Fig S1 were not retrieved. This short-term model panel does not establish universal HRAS dependence or durable control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor-volume response in four HRAS-mutant PDX modelsGrowth versus vehicle All four mutant models suppressed relative to vehicle; n=3 per group. Fig 5B annotations: HN1420 ***, HN2579 ***, HN2581 **, HN3504 ***; caption defines **P<0.01 and ***P<0.001. Error-bar semantics are not specified in the caption.[1]
Tumor-volume change in six HRAS-wild-type PDX models during tipifarnib treatmentChange from pretreatment volume Positive volume change in all six wild-type models in Fig 5A; exact percentages not extracted.[1]

Conditions shared by the study groups

Route
Oral
Frequency
Twice daily
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tipifarnib: HRAS-mutant PDX panel
60 mg/kg
Vehicle-treated group for each modelSuppressed tumor growth compared with vehicle in all four models.[1]
Tipifarnib: HRAS-wild-type PDX panel
60 mg/kg
Own pretreatment tumor volume in Fig 5A; supplemental vehicle curves not retrieved.All six bars show positive tumor-volume change on treatment.[1]
Tipifarnib: HRAS-mutant PDX panel
Model: HN1420 (A146T), HN2579 (G12S), HN2581 (G13R), HN3504 (K117N); n=3 per group
Treatment course: Caption approximately 20 days; HN3504 followed beyond day 30 in Fig 5B.
Reported limits: Vehicle composition and exact model-specific treatment stop times not retrieved.
Tipifarnib: HRAS-wild-type PDX panel
Model: HN5123, HN5111, HN5115, HN2609, HN3411, HN0626; caption describes groups of three
Treatment course: Approximately 20 days per Fig 5A caption.
Reported limits: No quantitative vehicle comparison adopted for wild-type PDXs; Fig S1 unavailable.
Methods and source locations

Compound reported in the paper: Tipifarnib; Compound label in the paper: Tipifarnib

Literature results for the named compound; tested material was supplied by Kura Oncology.

Results S16; Fig 5A-B and caption; Methods in vivo mouse experiments and analysis

Tumor-volume response in four HRAS-mutant PDX models: Serial tumor-volume assessment; no exact means or percent inhibition inferred from curves. — Fig 5B and caption; Results S16

Tumor-volume change in six HRAS-wild-type PDX models during tipifarnib treatment: Waterfall plot; these bars compare before and after treatment, not a numerical treated/vehicle ratio. — Fig 5A and caption; Results S16

Tipifarnib: HRAS-mutant PDX panel · Fig 5B and caption; Results S16

Tipifarnib: HRAS-wild-type PDX panel · Fig 5A and caption; Results S16

Neuroblastoma combination treatment and sEV add-back

Animal study · Subcutaneous 9464D-GD2 neuroblastoma in immunocompetent C57BL/6J mice, 8–10 weeks old; equal male/female representation described in shared methods. [2]

Tipifarnib and dinutuximab each showed mild antitumor activity; the combination reduced tumor growth and weight more than either agent. sEV add-back reversed the single-agent tipifarnib effect, while the tumor-weight increase after add-back to the combination did not reach statistical significance (p=0.086). Additional farnesylation-dependent effects cannot be excluded.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume over time and endpoint tumor weightGrowth and weight comparisons Mean±SEM. Group n: PBS 7; tipifarnib 11; tipifarnib+sEVs 10; dinutuximab 8; dinutuximab+tipifarnib 10; triple combination 10. Combination reduced growth/weight versus either agent; sEVs rescued the single-agent tipifarnib effect. No exact means extracted.[2]
Tumor weight after sEV addition to dinutuximab plus tipifarnibPairwise p value p=0.086; increased weight did not reach statistical significance.[2]

Conditions shared by the study groups

Treatment course
One week after inoculation to endpoint day 24.
Vehicle
20% w/v hydroxypropyl-β-cyclodextrin, pH 2.5 for oral drug/vehicle; PBS for injections.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PBS + oral vehicle
PBS control and equivalent oral vehicle
PBS plus oral vehicle; monotherapy and two-drug controls as appropriate.Control[2]
Tipifarnib
Tipifarnib 25 mg/kg per administration
PBS plus oral vehicle; monotherapy and two-drug controls as appropriate.Mild antitumor activity versus control.[2]
Tipifarnib + sEVs
Tipifarnib 25 mg/kg per administration; sEVs 20 µg/mouse
PBS plus oral vehicle; monotherapy and two-drug controls as appropriate.sEVs restored tumor growth/weight toward control compared with tipifarnib alone.[2]
Dinutuximab
Dinutuximab 25 µg/mouse
PBS plus oral vehicle; monotherapy and two-drug controls as appropriate.Mild antitumor activity.[2]
Dinutuximab + tipifarnib
Tipifarnib 25 mg/kg per administration; Dinutuximab 25 µg/mouse
PBS plus oral vehicle; monotherapy and two-drug controls as appropriate.Reduced growth and tumor weight compared with either agent alone.[2]
Dinutuximab + tipifarnib + sEVs
Tipifarnib 25 mg/kg per administration; Dinutuximab 25 µg/mouse; sEVs 20 µg/mouse
PBS plus oral vehicle; monotherapy and two-drug controls as appropriate.Tumor weight increased versus the two-drug combination; p=0.086, not statistically significant.[2]
PBS + oral vehicle
Model: 9464D-GD2 tumors in C57BL/6J mice; n=7
Route: Tail vein PBS; oral gavage vehicle
Frequency: PBS twice weekly; oral vehicle twice daily
Tipifarnib
Model: 9464D-GD2 tumors in C57BL/6J mice; n=11
Route: Tipifarnib: oral gavage
Frequency: Tipifarnib: twice daily
Tipifarnib + sEVs
Model: 9464D-GD2 tumors in C57BL/6J mice; n=10
Route: Tipifarnib: oral gavage; sEVs: tail vein
Frequency: Tipifarnib: twice daily; sEVs: twice weekly
Dinutuximab
Model: 9464D-GD2 tumors in C57BL/6J mice; n=8
Route: Dinutuximab: tail vein
Frequency: Dinutuximab: twice weekly
Dinutuximab + tipifarnib
Model: 9464D-GD2 tumors in C57BL/6J mice; n=10
Route: Tipifarnib: oral gavage; Dinutuximab: tail vein
Frequency: Tipifarnib: twice daily; Dinutuximab: twice weekly
Dinutuximab + tipifarnib + sEVs
Model: 9464D-GD2 tumors in C57BL/6J mice; n=10
Route: Tipifarnib: oral gavage; Dinutuximab: tail vein; sEVs: tail vein
Frequency: Tipifarnib: twice daily; Dinutuximab: twice weekly; sEVs: twice weekly
Methods and source locations

Compound reported in the paper: Tipifarnib; Compound label in the paper: Tipifarnib

Literature results for named tipifarnib; supplier attribution is not experiment-specific.

Fig 6A-D and caption; Results s3-5; Materials and methods: Drugs and antibodies, Animal experiments, Statistical analysis

Tumor volume over time and endpoint tumor weight: Caliper tumor-volume monitoring; endpoint excised tumor weight; caption reports Student’s t-test for weights. — Fig 6B-D and caption; Results s3-5; Animal experiments

Tumor weight after sEV addition to dinutuximab plus tipifarnib: Student’s t-test as reported in Fig 6C caption; no exact weight or effect size digitized. — Fig 6C; Results s3-5, paragraph beginning To validate

PBS + oral vehicle · Fig 6A-D and caption; shared Drugs and antibodies and Animal experiments

Tipifarnib · Fig 6A-D and caption; shared Drugs and antibodies and Animal experiments

Tipifarnib + sEVs · Fig 6A-D and caption; shared Drugs and antibodies and Animal experiments

Dinutuximab · Fig 6A-D and caption; shared Drugs and antibodies and Animal experiments

Dinutuximab + tipifarnib · Fig 6A-D and caption; shared Drugs and antibodies and Animal experiments

Dinutuximab + tipifarnib + sEVs · Fig 6A-D and caption; shared Drugs and antibodies and Animal experiments

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 192185-72-1
Applications FTase inhibitor
Formula C27H22Cl2N4O
Molecular Weight 489.4
Synonyms IND 58359; R115777; Zarnestra
SMILES
CN1C=NC=C1[C@@](C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 14 mg/mL (28.6 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
15% Captisol+citrate vehicle

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tipifarnib (Zarnestra) Research References

  1. [1] Gilardi M, Wang Z, Proietto M, et al. Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas Molecular cancer therapeutics (2020). PMID: 32727882 DOI: 10.1158/1535-7163.mct-19-0958 Source material
  2. [2] Liu X, Wills CA, Chen L, et al. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy Journal for immunotherapy of cancer (2022). PMID: 35483745 DOI: 10.1136/jitc-2021-004399 Source material

Publications

1 publication citing this product

  1. Xiaoming Liu, .et al. , J Immunother Cancer, 2022, Apr;10(4):e004399 PMID: 35483745

Added to your cart

View Cart Checkout
Loading...